August 11, 2014 Phase 3 ASPIRE Trial of Carfilzomib (ONO-7057), a proteasome inhibitor, in patients with relapsed multiple myel
Multiple Myeloma in Session 2015: An Online Journal Club for Hematology/Oncology Fellows This program is supported by educational grants from Celgene Corporation. - ppt download
Phase 3 Studies Show Kyprolis (Carfilzomib) Extends Progression Free Survival for Relapsed/Refractory Myeloma - HealthTree for Myeloma
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial | PLOS Medicine
Frontiers | Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR | Leukemia
Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews - ScienceDirect
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study - The Lancet Oncology
Carfilzomib in multiple myeloma
Clinical Challenges in Patients With Relapsed/Refractory Multiple Myeloma (Transcript)
Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR | Leukemia
Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma - YouTube
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma | Leukemia
Carfilzomib in multiple myeloma
KRd vs Rd Study Results & Efficacy | KYPROLIS® (carfilzomib)
Kyprolis Label to Include Positive Data of Aspire Trial in Advanced Multiple Myeloma Patients
Relapsed and Refractory Myeloma - ppt video online download
Carfilzomib in multiple myeloma
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® ( carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Interim Results of ASPIRE Trial | Int'l Myeloma Fndn
PDF) Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III
PDF) Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: Secondary analysis from the phase 3 ASPIRE study
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
KYPROLIS-carfilzomib - Biotech Due Diligence
Design of randomized phase 3 trials. A, ASPIRE trial; B, ENDEAVOR... | Download Scientific Diagram
Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment | Blood Cancer Journal
